125 related articles for article (PubMed ID: 36267796)
1. Sources of bias for single-arm phase II cancer clinical trials.
Jung SH
Ann Transl Med; 2022 Sep; 10(18):1037. PubMed ID: 36267796
[TBL] [Abstract][Full Text] [Related]
2. Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials.
Jung SH
Contemp Clin Trials; 2015 May; 42():9-17. PubMed ID: 25749311
[TBL] [Abstract][Full Text] [Related]
3. Optimal designs for phase II clinical trials with heterogeneous patient populations.
Liu L; Cao S; Jung SH
J Biopharm Stat; 2023 Jan; 33(1):1-14. PubMed ID: 35793231
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
[TBL] [Abstract][Full Text] [Related]
5. Stopping for efficacy in single-arm phase II clinical trials.
Rahman R; Iftakhar Alam M
J Appl Stat; 2022; 49(10):2447-2466. PubMed ID: 35757036
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II clinical trials.
Jung SH; Sargent DJ
J Biopharm Stat; 2014; 24(4):802-16. PubMed ID: 24697589
[TBL] [Abstract][Full Text] [Related]
7. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
Pond GR; Abbasi S
Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
[TBL] [Abstract][Full Text] [Related]
8. Applying a phase II futility study design to therapeutic stroke trials.
Palesch YY; Tilley BC; Sackett DL; Johnston KC; Woolson R
Stroke; 2005 Nov; 36(11):2410-4. PubMed ID: 16224086
[TBL] [Abstract][Full Text] [Related]
9. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
[TBL] [Abstract][Full Text] [Related]
10. A varying-stage adaptive phase II/III clinical trial design.
Dong G
Stat Med; 2014 Apr; 33(8):1272-87. PubMed ID: 24273128
[TBL] [Abstract][Full Text] [Related]
11. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
Levin B; Thompson JL; Chakraborty B; Levy G; MacArthur R; Haley EC
Clin Trials; 2011 Aug; 8(4):398-407. PubMed ID: 21737464
[TBL] [Abstract][Full Text] [Related]
12. Estimation of the odds ratio from multi-stage randomized trials.
Cao S; Jung SH
Pharm Stat; 2024 Mar; ():. PubMed ID: 38462496
[TBL] [Abstract][Full Text] [Related]
13. Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility.
Kimani PK; Todd S; Stallard N
Stat Med; 2013 Jul; 32(17):2893-910. PubMed ID: 23413228
[TBL] [Abstract][Full Text] [Related]
14. A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules.
Wang J; Ma J; Cai C; Daver N; Ning J
Stat Med; 2021 Sep; 40(21):4629-4639. PubMed ID: 34101217
[TBL] [Abstract][Full Text] [Related]
15. Optimal two-stage log-rank test for randomized phase II clinical trials.
Kwak M; Jung SH
J Biopharm Stat; 2017; 27(4):639-658. PubMed ID: 27050043
[TBL] [Abstract][Full Text] [Related]
16. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility.
Walter SD; Han H; Briel M; Guyatt GH
Stat Med; 2017 Apr; 36(9):1506-1518. PubMed ID: 28183155
[TBL] [Abstract][Full Text] [Related]
17. Phase II cancer clinical trials with heterogeneous patient populations.
Jung SH; Chang MN; Kang SJ
J Biopharm Stat; 2012; 22(2):312-28. PubMed ID: 22251176
[TBL] [Abstract][Full Text] [Related]
18. Some design considerations incorporating early futility for single-arm clinical trials with time-to-event primary endpoints using Weibull distribution.
Waleed M; He J; Phadnis MA
Pharm Stat; 2021 May; 20(3):610-644. PubMed ID: 33565236
[TBL] [Abstract][Full Text] [Related]
19. Two-stage seamless transition design from open-label single-arm to randomized double-arm clinical trials.
Shi H; Yin G
Stat Methods Med Res; 2018 Jan; 27(1):158-171. PubMed ID: 28034171
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
